EUVIMEDEUVIMED entdecken
Crossref

Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India

Inderpaul Singh Sehgal, Ritesh Agarwal, Valliappan Muthu iD, Sahajal Dhooria, Kuruswamy Thurai Prasad, Shivaprakash M Rudramurthy iD, Ashutosh Nath Aggarwal, Mandeep Garg, Arunaloke Chakrabarti iD

Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)

DOI: 10.1093/jac/dkag200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 08.06.2026. Verfasst von Inderpaul Singh Sehgal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Deoxycholic Acid, Amphotericin B, Antifungal Agents, Pulmonary Aspergillosis. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic pulmonary aspergillosis (CPA) requires prolonged oral azole therapy, yet 30%–40% experience relapse after treatment discontinuation. The role of nebulized amphotericin B (NAB) in CPA as a maintenance therapy remains unexplored.

Methods

We retrospectively reviewed CPA patients treated with NAB deoxycholate (10 mg twice daily) preparation administered either on alternate days (three times weekly) or six times weekly (6/7-day). The primary objective was to compare the efficacy and safety of these two dosage schedules in maintaining CPA remission.

Results

We included 36 subjects (28 chronic cavitary pulmonary aspergillosis, 8 chronic fibrosing pulmonary aspergillosis ). Most received oral itraconazole (n = 34) for a median duration of 12 months before NAB initiation. Patients received NAB on alternate days (n = 16) or 6/7-day (n = 20) for a median duration of 11 months. Of 34 evaluable patients with a median follow-up of 27 months, remission was maintained in 23 (67.6%) during NAB therapy, with significantly higher rates with 6/7-day versus alternate-day therapy (16/19 [84.2%] versus 7/15 [46.7%]; P = 0.020). CPA relapse occurred in 11 patients (32.4%), more frequently with alternate-day treatment (8/15 [53.3%] versus 3/19 [15.8]; P = 0.020). Adverse events occurred in eight patients (22.2%), including bronchospasm (n = 5) and haemoptysis (n = 1); two discontinued NAB due to intolerance.

Conclusion

Nebulized amphotericin B deoxycholate maintained CPA remission in two-thirds of patients, with 6/7-day administration achieving significantly better outcomes than alternate-day therapy. Prospective randomized controlled trials are needed to establish NAB as standard maintenance therapy in CPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deoxycholic AcidAmphotericin BAntifungal AgentsPulmonary AspergillosisHumansRetrospective StudiesTertiary Care CentersFemaleTreatment OutcomeIndiaMiddle AgedMaleDrug CombinationsAdultAdministration, InhalationAgedNebulizers and VaporizersChronic Disease

Substanzen

Deoxycholic AcidAmphotericin BAntifungal Agentsamphotericin B, deoxycholate drug combinationDrug Combinations

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Doodhadhari Burfani Hospital, Haridwar, India.

ORCID-Profile: Valliappan Muthu, Shivaprakash M Rudramurthy, Arunaloke Chakrabarti

Zitieren

APA

Sehgal, I. S., Agarwal, R., Muthu, V., Dhooria, S., Prasad, K. T., Rudramurthy, S. M., Aggarwal, A. N., Garg, M., & Chakrabarti, A. (2026). Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag200

Vancouver

Sehgal IS, Agarwal R, Muthu V, Dhooria S, Prasad KT, Rudramurthy SM, et al. Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag200

BibTeX
@article{Sehgal2026,
  author = {Sehgal, Inderpaul Singh and Agarwal, Ritesh and Muthu, Valliappan and Dhooria, Sahajal and Prasad, Kuruswamy Thurai and Rudramurthy, Shivaprakash M and Aggarwal, Ashutosh Nath and Garg, Mandeep and Chakrabarti, Arunaloke},
  title = {Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {7},
  doi = {10.1093/jac/dkag200}
}
Kostenlos starten →